Ann: PharmAust's Phase 1 Study Data Presented at Major Conference, page-10

It would seem Dr Thurn and John Clark put a lot of thought into the contents of the PAA Scientific Advisory Board pie.
Dr Phillip White and Dr Melanie Quintana will be making the presentation.

From here: https://investorhub.pharmaust.com/announcements/6212289

Dr Melanie Quintana
- Director and Senior Statistical Scientist at Berry Consultants, where she specialises in
designing Bayesian adaptive clinical trials across a wide range of therapeutic areas. Her work has included
numerous examples in designing platform trials, including the HEALEY ALS Platform Trial and clinical trials in
rare and progressive diseases, focusing on developing disease progression models to design better and more
powerful clinical trials. Before joining Berry Consultants, Melanie earned her PhD in Statistics from Duke University
and pursued a Postdoc in Biostatistics at The University of Southern California.

The European Network to Cure ALS, ENCALS, conference in Stockholm Sweden could be a pivotal point in time for PAA.

A very impressive group of folk with connections to PAA attending ENCALS
Prof Leonard van den Burg Chair of ENCALS and PAA SAB member.
Dr Melanie Quintana co prepresenting data from PharmAust’s successful Phase 1 MEND study and SAB member.
John Clark Chief Operating Officer PAA
Sergio Duchini Chair PAA

Good luck to all